The importance of the intestine in regulating post-prandial glucose levels unfolded over the latter half of the 20th century. Observations in the early 20th century demonstrated that intestinal extracts could alleviate diabetes, but these studies were overlooked. 1,2 It was not until the 1960s that the 'enteroinsular axis' and the incretin effect were defined. The enteroinsular axis is a network of neural and endocrine signals between the intestine and the pancreas that promote insulin release in response to feeding. 
The expression and activity of DPP-4 in certain tissues and blood plasma can vary significantly in response to disease, injury or inflammation (reviewed elsewhere). 21, 22 It is therefore not surprising that the physiological role of DPP-4 is wide-ranging. It is capable of interacting with large proteins such as collagen, fibronectin and adenosine deaminaseas as well as many peptide substrates (see review). 23 Among the most commonly recognised substrates of DPP-4 are several chemokines affecting the immune system, several neuropeptides with wide-ranging actions and the counter-regulatory hormone glucagon.
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Degradation of GLP-1 and GIP by DPP-4 in vitro was first demonstrated by Mentlein and co-workers. 24 They observed the enzymatic removal of N-terminal dipeptides His 7 -Ala 8 and Tyr 1 -Ala 2 from GLP-1 and GIP, respectively, when incubated with DPP-4 purified from the human placenta. Importantly, they went on to observe that GLP-1 and GIP were similarly degraded when incubated in human serum. 24 Subsequently, it was confirmed that DPP-4-mediated metabolism of GLP-1 and GIP also occurred in vivo. 24, 25 This action of DPP-4 reduces the in vivo half-life of GLP-1 and GIP to less than two minutes. [25] [26] [27] Since the active forms of incretin hormones are GLP-1(7-36) amide and GIP(1-42), degradation by DPP-4 leads to inactivation with the accumulation of major degradation fragments GLP-1(9-36) amide and GIP(3-42), respectively.
The receptor binding characteristics and actions of these fragments have been elucidated. GLP-1(9-36) amide and GIP(3-42)
are both non-insulinotropic peptides and it was initially suggested that these were relatively inert and inactive metabolites. [26] [27] [28] The affinity of GLP-1(9-36) amide for the GLP-1 receptor is 100-fold lower than that of the parent molecule and it appears to act as a weak receptor antagonist. [29] [30] [31] While GLP-1(9-36) amide does not antagonise the insulinotropic activity of physiological GLP-1(7-36) amide concentrations in vivo, there is some evidence that this metabolite possesses weak antihyperglycaemic activity through a mechanism not involving insulin secretion.
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Following truncation by DPP-4, the receptor affinity of GIP(3-42) is approximately four-fold lower than that of GIP(1-42). 33 GIP(3-42) has been shown to antagonise the GIP receptor in vitro. 34, 35 However, different results have been generated by in vivo studies. [34] [35] [36] Thus, although GIP(3-42) antagonises GIP-stimulated adenosine 3'5' cyclic monophosphate (cAMP) production and insulin secretion in vitro, it does not behave as an antagonist at physiological concentrations in vivo. 33 Indeed, a pharmacological dose of GIP(3-42) (25nmol/kg) administered to obese diabetic (ob/ob) mice once daily for 14 days enhanced insulin sensitivity and improved glycaemic control. 36 This appears to involve extrapancreatic mechanisms aroused by compromised GIP action, leading to improved insulin sensitivity (for a review see Irwin and Flatt). 37 However, during studies with GIP(3-42)
or GLP-1(9-36) amide there were no effects on bodyweight, food intake, pancreatic insulin content or islet morphology. improved glucose tolerance and increased the circulating levels of active GLP-1. 49 The effectiveness of the inhibitor valine-pyrrolidide was demonstrated in high-fat-fed mice. Valine-pyrrolidide improved glucose tolerance and potentiated the insulin response to intra-gastric glucose.
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Early experiments exploring possible combinatorial therapies involving DPP-4 inhibitors were undertaken in diabetic mouse models.
Combining vildagliptin with rosiglitazone did not provide any additional efficacy to rosiglitazone alone; however, it did appear to reduce common side effects such as weight gain and haemodilution.
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Combining a DPP-4 inhibitor with an alpha-glucosidase inhibitor had an additive effect on glucose tolerance and increased active GLP-1 levels.
52 Wider dissemination of pre-clinical studies with DPP-4 inhibitors, and particularly their adoption into clinical trials, has led to a proliferation in the number of DPP-4 inhibitor compounds under investigation. The outcomes of these trials remain to be seen. The effects of gliptins are generally additive to those of other antidiabetic agents, provided there is adequate remaining beta-cell function. Usage has been mainly in combination with agents that improve insulin sensitivity (metformin or a thiazolidinedione).
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Clinical Use of Gliptins
However, gliptins can also be used with a sulphonlyurea or meglitinide to further enhance the insulin response because incretins act on beta-cells via a separate cellular mechanism involving specific G-protein-coupled receptors.
Monotherapy with a gliptin carries a low risk of interprandial hypoglycaemia, although hypoglycaemia is more evident when gliptins are used in combination with other agents, notably sulphonylureas. [75] [76] [77] This reflects the mode of action via incretins to potentiate nutrient-induced insulin secretion, but not to initiate insulin secretion at low glucose concentrations. Also, the glucagon-lowering effect of GLP-1 is lost at low glucose concentrations, helping to preserve an acute counter-regulatory response. 78 The extent to which gliptins raise active GLP-1 concentrations does not appear to be sufficient to significantly reduce the rate of gastric emptying, hence gliptins do not tend to cause the nausea that is 
Safety and Tolerability of Gliptins
The inhibition of DPP-4 could potentially extend the circulating half-lives of many biologically active peptides with an Ala or Pro residue penultimate to the N-terminus, such as bradykinin, encephalins, neuropeptide Y, gastrin-releasing polypeptide, substance P and monocyte chemoattractant protein-1. Thus, gliptins might conceivably affect vasoreactivity, monocyte behaviour, gastrointestinal motility and growth, as well as having an incretin-enhancing effect. 78, 81 However, there has been no evidence to date that gliptin therapy has any clinically significant or measurable effects on these physiological functions.
Since DPP-4 doubles as the CD-26 T-cell activating antigen, this has raised suspicion that gliptins could interfere with immune function. diseases. At this stage it is too early to tell whether DPP-4 inhibitors could play a role in these actions. Their use will need to be reviewed periodically as and when new evidence comes to light.
Cardioprotective Effects
Patients with diabetes are characterised by an increased risk of developing both microvascular complications (e.g. retinopathy, nephropathy and neuropathy) and atherosclerotic macrovascular disease, potentially leading to the development of peripheral vascular disease, stroke and heart failure. 87 In the UK, cardiovascular disease (CVD) is the leading cause of mortality and is linked to premature death in up to 40% of the population. 87 Patients with diabetes are characterised by significantly elevated CVD risk compared with normoglycaemic individuals. 88, 89 The Framingham Heart Study determined that heart failure was twice as common in men with diabetes and five times as common in women with diabetes who were 45-74 years of age compared with the normal population and that this association was even stronger in younger patients. The emerging cardiovascular actions of GLP-1 and the potential for GLP-1 as a treatment for CVD in both diabetic and non-diabetic patients has recently been reviewed in depth. 93 
Neuroprotective Effects
The central effects of GLP-1 to inhibit feeding are widely appreciated.
They appear to be mediated by GLP-1 receptors located in the arcuate nucleus and other hypothalamic regions. Neuroprotective effects of increased circulating incretin levels passing into the brain and/or by activation of peripheral sensory neural pathways are worthy of consideration, especially given their increasing recognition in glucoregulatory incretin effects.
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Conclusion
From their inception around a decade ago, gliptin drug therapies for type 2 diabetes have rapidly gone from concept to pre-clinical development to clinical adoption. Factors contributing to this are:
• the characterisation of the inactivation of GLP-1 and GIP by DPP-4;
• the parallel development of incretin analogues and mimetics; and
• the proven efficacy and suitability of gliptins for oral administration.
Currently, diabetologists have a selection of three approved gliptin therapies for managing hyperglycaemia, with further additions likely.
Gliptins are suitable for mono-and combination therapy. They add to the growing array of antidiabetic drugs now available. 
